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Abstract
Neutropenic patients with haematological malignancies are at high risk of invasive fungal disease (IFD). Due to limitations in speciﬁc
procedures to establish an early diagnosis of IFD, two historical unpowered studies suggested, three decades ago, that giving an empirical
antifungal treatment to patients with persistent or recurrent fever under broad-spectrum antibacterials, could reduce the risk of IFD. For
cost and toxicity reasons, this strategy became debated when modern imaging and indirect biological markers became available. Different
pre-emptive strategies, either based on lung imaging, galactomannan antigenaemia, fungal PCR, or a combination of several parameters, were
designed with the goal of restricting the administration of antifungals to the more at-risk patients with early signs of IFD. Almost all
pre-emptive studies showed or suggested a reduction of administration and cost of antifungals during neutropenic phases. However, the
clinical pertinence and safety of the strategy, and mainly its optimal design, are still pending. This paper reviews the evolution of these
strategies and how they may be implemented in the haematology ward.
Keywords: Empirical antifungal therapy, fungal PCR, galactomannan, invasive fungal disease, invasive fungal infection, neutropenia,
pre-emptive antifungal therapy
Article published online: 27 November 2013
Clin Microbiol Infect 2014; 20 (Suppl. 6): 27–35
Corresponding author: C. Cordonnier, Haematology Department,
Henri Mondor Hospital, 94000 Creteil, France
E-mails: carlcord@club-internet.fr;
catherine.cordonnier@hmn.aphp.fr
Introduction
Prolonged neutropenia is a main risk factor for invasive fungal
disease (IFD). Patients with haematological malignancies, and
especially those with acute myeloid leukaemia (AML), or those
who undergo allogeneic, myeloablative, haematopoietic stem
cell transplantation (HSCT) have chemotherapy-induced neu-
tropenic phases of long duration—classically more than
10 days—which make them at higher risk of IFD [1]. Although
new antifungal drugs are available, the 12-week mortality rate
of IFD remains between 29% [2] and 47.8% [3] in invasive
aspergillosis (IA), and between 29.6% [4] and 40% [5] in
invasive candidiasis. Additionally, in patients with acute
leukaemia, even though the patient initially survives the
infection, IFD has a negative impact on the overall outcome,
by modifying the choice and timing of chemotherapy or of the
conditioning regimen of stem cell transplantation [6].
To avoid the onset of IFD in neutropenic patients, three
approaches have been developed, which are often combined:
antifungal prophylaxis, empirical antifungal therapy and
pre-emptive antifungal approaches. Before efﬁcient antifungal
prophylaxis was available, and before indirect biological
markers and effective imaging were assessed, the only
acceptable approach was empirical antifungal therapy in
patients with persistent or recurrent unexplained fever
refractory to broad-spectrum antibiotics [7,8]. The present
manuscript will review the development of pre-emptive
antifungal approaches in high-risk neutropenic patients.
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Empirical Antifungal Therapy in High-risk
Neutropenic Patients: an Old, and Debated
Story
Identiﬁed a long time ago from autopsy series, the risk of
fungal death is a major concern in haematology [3,9–12].
Following the success of the antibacterial empirical approach
in febrile neutropenic patients [13], it was hypothesized that
an early empirical antifungal treatment could reduce the risk
of IFD in this setting, at a time when there were no
sensitive imaging or biological procedures for IFD, no
routine use of bronchoalveolar lavage, and almost no other
efﬁcient anti-mould therapy than deoxycholate amphoteri-
cin-B. This approach was explored in two historical, open,
studies whose conclusions are criticized 30 years later for
methodological reasons [14,15]. In the ﬁrst study, 50 febrile
neutropenic patients on antibacterial agents for 7 days were
randomized to continuing with the same antibacterials only,
stopping the antibacterials, or adding deoxycholate ampho-
tericin-B to the antibacterials [8]. The administration of
amphotericin-B was associated with a decreased number of
IFD and of fungal deaths (1/18 vs 4/16 and 3/16 in the other
groups, respectively). This was the starting point for a larger
study including 132 neutropenic patients who were ran-
domized from day 4 of fever to additionally receive, or not
receive, deoxycholate amphotericin-B [7]. Although there
was a lower number of IFD in the deoxycholate amphoter-
icin-B group (1/68 vs 4/64), the difference was not signiﬁcant
but there were fewer fungal deaths (0/68 vs 4/64, p 0.05).
Although short on facts, the strategy was widely adopted by
the haematology community and was later reinforced by
papers showing that any delay in the treatment of IFD is
deleterious [16,17]. However, these studies have many
limitations: unblinded design, few patients, no difference in
the IFD rate [15].
Almost all new antifungal drugs, especially liposomal
amphotericin-B [18], voriconazole [19] and caspofungin
[20], were assessed in the empirical indication. The inves-
tigators initially used deoxycholate amphotericin-B as the
standard [18], then liposomal amphotericin-B [19,20], which
was as effective and less toxic than amphotericin-B and was
associated with less breakthrough IFD [18]. Caspofungin was
as effective as liposomal amphotericin-B but generally better
tolerated [20]. A large study failed to show that voricona-
zole was non-inferior to liposomal amphotericin-B [19].
Other antifungals were also evaluated [15]. All these trials
raised methodological concerns, using sophisticated, com-
posite endpoints, mainly based on drop in fever, or focusing
on toxicity as a primary endpoint [21–23].
Years later, the empirical strategy is widely used, easy to
apply, does not need costly equipment, and is still endorsed by
international guidelines [15,24]. With such a strategy, 30–70%
of febrile neutropenic patients receive antifungals, usually from
day 4–5 of persistent fever to the end of neutropenia. Overall,
one may consider that the empirical approach is more to be
debated than the choice of the optimal antifungal drug in this
indication, but we now have indirect markers or imaging
procedures to develop a more targeted strategy.
The Concept of a ‘Pre-emptive’, Diagnostic-
driven Strategy
There is no consensual deﬁnition of a ‘pre-emptive antifungal
strategy’, but one common goal is to restrict the administra-
tion of antifungals to patients at the very early phase of IFD,
and so decrease toxicity, costs and risk of emerging resistance
[25,26]. Some authors prefer alternative wordings like ‘diag-
nosis-driven’ or ‘targeted’, but this is a sterile debate because
the optimal strategy is not deﬁned. Most of these approaches
have mainly focused on the risk of ﬁlamentous infections,
mainly IA, using galactomannan (GM) screening and computed
tomography (CT) scans.
The wording ‘pre-emptive’ has been adopted by the
haematology community on the experience of pre-emptive
therapy for cytomegalovirus infection after HSCT, a situation
where infection and disease are clearly distinguished, and
where giving an antiviral drug on the basis of a biomarker
without symptoms prevents the onset of disease [27–29]. The
fungal issue is not the same:
 Many studies have explored the beneﬁt of GM or PCR
screening in neutropenic patients. However, no study
compared a strategy where such a marker triggered
antifungal administration with a strategy of ‘wait-and-see’
for IFD. The only comparative trials were done with an
empirical, fever-based strategy, as the control arm [30–34].
 Some authors found that GM does not precede major signs of
IA on CT scan [35]. Similarly, there is no proof that serum or
blood fungal PCR, performed according to the more recent
guidelines [36], either precedes or clearly diagnoses IA.
Indeed, the fungal risk going from no IFD to proven/probable/
possible IFD during neutropenia has to be thought of as a daily
increasing process because time (duration of neutropenia) is
essential in the fungal risk [37–39]. This tiny margin is well
illustrated by this deﬁnition of pre-emptive therapy [40]:
‘Betweenover- andundertreatment of invasive fungal disease’.
In fact, in most pre-emptive studies, the investigators
combined biological, clinical and imaging triggers to administer
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antifungals, in order to be in the best position to catch IFD at a
very early stage.
Feasibility, and Observational or Retrospe-
ctive Studies on Pre-emptive Antifungal
Strategies
One of the main concerns in assessing pre-emptive strategies
is the optimal methodology to use. Blinded or placebo-
controlled studies have not been performed and would be
practically difﬁcult. Several studies were described as ‘obser-
vational’ but in fact were retrospective (Table 1).
The feasibility of a pre-emptive approach in high-risk
neutropenic patients was ﬁrst shown by Maertens et al. [41].
The authors assessed 136 high-risk neutropenic episodes in 88
haematology patients. Most patients had AML, all received
ﬂuconazole prophylaxis, and were managed in HEPA-ﬁltered
rooms. Patients were assessed daily by a blood GM test. Chest
CT scan, and eventually a bronchoalveolar lavage were
performed in the case of two consecutive GM tests (index
>0.5), persistent fever for >5 days, or recurrent fever, new
pulmonary inﬁltrate on chest X-ray, or mould colonization.
Patients received liposomal amphotericin-B only where there
was IFD. The strategy reduced the use of antifungals from 35%
(the rate expected in an empirical approach) to 7.7%.
Additionally, the GM test was positive in 10 afebrile patients.
One case of zygomycosis and two cases of invasive candidiasis
were not detected by the strategy. Finally, the incidence of
proven/probable IFD was 15% per episode, and 24% per
patient.
From this preliminary experience, the haematologists
explored alternative strategies to empirical therapy. Several
studies were reported, based on imaging only [42], combina-
tions of GM and CT scan [43], purely clinical criteria [44], or
on an intensive diagnostic work-up triggered by persistent
fever or clinical suspicion of IFD [45] (summarized in Table 1).
However, many methodological issues preclude clear conclu-
sions, the main caveat being the lack of comparison to
alternative approaches and especially to a purely empirical, or
prophylactic approach. Most authors agree on the hypothe-
sized reduction (>50%) of antifungal consumption by the
pre-emptive approach [41,45]. However, three issues deserve
comment: (i) the IFD incidence rates in these studies were
often in the higher range for such populations in the
pre-emptive studies [1,41,45]; (ii) survival (when given) was
never compared with that of other strategies; (iii) the larger
observational study with 397 patients [43] managed either with
an empirical or a pre-emptive approach, showed that the rate
of IFD (23.7% vs 7.4%, p <0.001) and the attributed and overall
mortality rates (22.5% vs 7.1%, and 15.9% vs 6.3%, respectively,
p 0.002) were signiﬁcantly higher in the pre-emptive group.
Comparative Trials
Few randomized studies, comparing a pre-emptive with an
empirical strategy, have been published (Table 2).
Hebart et al. assessed the use of a panfungal PCR during the
ﬁrst 3 months following allogeneic HSCT [32]. They compared
a fever-driven antifungal strategy with a hybrid both fever--
driven and PCR-driven strategy in 403 transplant recipients.
Although survival was better at day 30 in the PCR group, this
beneﬁt was no longer found at day 100. Moreover, more
patients received antifungals in the PCR-based group when
compared with the empirical group. This can be explained in
part by the addition of an empirical approach after 5 days of
persistent febrile neutropenia in the PCR-driven group, which
led to the provision of antifungals to PCR-negative patients, a
strategy that disagrees with the negative predictive value of the
PCR shown by other authors [46]. Additionally, the high rate
of PCR positivity (28.3% of the patients) might suggest false
positives with the endpoint format of the PCR used at that
time [47,48].
Another study based on a weekly whole-blood real-time
PCR targeting Candida and Aspergillus spp. evaluated 99 patients
who received a reduced-intensity conditioning allogeneic
HSCT [30]. In the case of a positive PCR, the patients were
planned to be randomized for liposomal amphotericin-B
treatment. Patients with fever of unknown origin for >3 days
despite administration of antibacterial agents were also
permitted to receive antifungals, regardless of the PCR results.
Only 21 of the 41 PCR-positive patients were randomized. The
rate of proven or probable IFD was not different in the patients
who received liposomal amphotericin-B on the basis of PCR
(0/8) when compared with the patients who did not (1/13).
Finally, the small number of patients, the lack of sensitivity of the
pan-fungal PCR, and the once-a-week screening do not permit
conclusions to be drawn on the relevance of the strategy.
In France, we ran a randomized trial comparing a purely
empirical versus a pre-emptive approach in 293 high-risk
neutropenic patients [31,39]. With 67% of AML patients, the
median duration of neutropenia <500/mm3 was 17.5 days.
Patients undergoing allogeneic HSCT were excluded. In the
empirical group, the administration of conventional or liposo-
mal amphotericin-B was exclusively fever-driven. In the
pre-emptive group, patients had a twice-weekly GM test from
the start of chemotherapy, and received deoxycholate ampho-
tericin-B or liposomal amphotericin-B only in the case of one
GM index being ≥1.5, or in the case of predeﬁned clinical
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symptoms or septic shock. Overall survival at day 42 after
inclusion (primary endpoint) was not statistically different in
both groups (97% in the empirical group vs 95% in the
pre-emptive group). As expected, amphotericin-B was given to
fewer patients and for shorter durations in the pre-emptive
group. However, two main issues pushed our group to go
further: (i) the incidence of proven/probable IFD was signif-
icantly higher in the pre-emptive group both in the whole
population (9.1% vs 2.7%; p <0.02) and in the higher risk
subgroup (AML inductions) (16.4% vs 3.8%; p <0.01), and (ii) in
this subgroup, we could not rule out the inferiority of the
pre-emptive approach on overall survival. Knowing the high
risk of IFD in this subgroup of patients, any doubts concerning
a loss in survival or gain of IFD risk makes it difﬁcult to
implement the pre-emptive strategy without further studies.
Second, the difference in IFD incidence cannot be considered
as incidental because this may impact on outcome [6]. A
similar trial was run by Tan et al. [34] but was underpowered
to draw any conclusion.
Recently, Morrissey et al. compared a hybrid empirical
approach (fever and CT scan driven), with a hybrid pre-emp-
tive approach using twice-weekly blood testing with GM and
two-nested PCR qualitative assays targeting Aspergillus spp. A
CT scan was performed in the case of positive biomarker(s) or
of persistent fever [33]. Among the 240 included patients,
most were allogeneic HSCT recipients. The choice of antifun-
gals was left to the initiative of the investigator. The use of
empirical antifungal drugs at week 26 (the primary endpoint)
was signiﬁcantly lower in the pre-emptive compared with the
empirical group (15% vs 32%; p 0.002). Overall survival was
not different between groups but the trial was not powered to
assess survival. IFD, and especially probable IA, were signiﬁ-
cantly more frequent in the pre-emptive group than in the
standard group (24.5% vs 4.1%; p <0.0001) but different
deﬁnitions of IFD were used in the two groups. Additionally,
11 of the 16 probable IA were documented through biological
markers only (GM and PCR: three; PCR alone: eight) without
any site of infection. Because the formats of the PCR assays
were nested and because the primers were designed to also
detect environmental Aspergillus species, the risk of false PCR
results from amplicon contamination and from environmental
mould DNA may have been high. Therefore, the results of this
trial are difﬁcult to interpret.
Is There Any Optimal Biomarker for
Neutropenic Patients?
Due to the predominance of IA over candidiasis in haematol-
ogy patients, GM has been logically the most explored method,
both as an indirect marker of IA [49–51] and as a guide for
pre-emptive antifungal therapy in neutropenic patients
[31,33,41,43,45]. Due to the diversity of the PCR assays
[52], the role of PCR, both in the diagnosis of IA and in guiding
a pre-emptive approach, remains investigative. Despite pitfalls,
and especially false-positive results, the advantage of GM over
PCR here is the result of the standardization of the GM test
and its strong validation by autopsies [53]. Although PCR has
been also explored for the early diagnosis of IA, the main
concerns about laboratory procedures [36,52] clearly moder-
ate the conclusions of the meta-analysis [54] performed on
studies published before the European consensus on PCR [36].
Consequently, we consider its use as still exploratory, pending
large studies ﬁtting with the European Aspergillus PCR Initiative
guidelines [55].
b-D-Glucan, which is a cell wall component of most fungi
including Aspergillus spp. and Candida spp. has been the purpose
of two meta-analyses in haematology patients [56,57]. The
sensitivity of the test appears to be lower in the haematology
ward than in the intensive care unit. b-D-Glucan has so far not
been used for guiding a pre-emptive strategy in neutropenic
patients.
One important issue to consider in assessing the
diagnostic yield of a fungal biomarker is the time-variation
of the fungal risk. What we expect from indirect biomarkers
in this setting is to anticipate overt disease. This is why we
chose to perform a time-dependent analysis in the transla-
tional research of the French study [31]. Serum samples
were frozen twice-weekly for b-D-glucan and quantitative
PCR, but the results were unknown to the clinicians. Later,
we assessed their performance for the early detection of IA
through a multi-state model in 185 high-risk patients with
AML, taking into account the daily evolution of the risk over
time during neutropenia [39]. With this approach, quantita-
tive PCR did accelerate the early detection of IA, while
b-D-glucan did not. In the setting of high-risk neutropenia,
and especially in patients receiving yeast prophylaxis, the
main concern remains IA, and the b-D-glucan test probably
does not add a lot to GM, whereas PCR could be useful in
combination with GM [39]. This hypothesis, however,
requires conﬁrmation.
How to Go Further?
The reasons why several trials did not solve the question of
whether to give up the empirical approach are multiple. The
design of prospective pre-emptive antifungal studies is a recent
issue and not yet ﬁxed. Many methodological concerns
emerge.
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 First, assessing the predictive value of biomarkers on the
diagnosis of IFD, and assessing a new clinical strategy based
on the same biomarkers and its impact on outcome
(survival, IFD incidence, cost) are different goals.
 Second, because of the evolution of the practices and
availability of new procedures, the control, so-called
‘empirical’, group is often no longer the same as in the
historical empirical approach, i.e. purely fever-based [7,8]. In
most centres, the empirical approach is now combined with
CT scans and/or GM use, whereas in pre-emptive
approaches, fever is sometimes added to the list of the
criteria for when to give antifungals [30,33]. This creates
some overlap between the two strategies, and some
confusion to implement conclusions of prospective trials in
routine practice. Additionally, the use of an approach initially
designed for neutropenic patients [8] in patients who may
not be neutropenic is confusing. This is the case for
allogeneic HSCT recipients, when this strategy is applied
until 3 months or more after transplant [32,33,42]. Admin-
istration of antifungals in immunocompromised but non-neu-
tropenic patients may often be delayed by 1–3 days to allow
direct diagnostic procedures, especially bronchoalveolar
lavage in the case of pneumonia, to cover several infectious
causes, and the strategy should not be the same as in
neutropenic patients.
 The optimal endpoints of such studies are debated. From a
haematological point of view, survival, and preferably
fungal-free survival, of deep neutropenia is the ﬁrst requisite
to beneﬁt from complete remission or engraftment. IFD is a
tricky endpoint because the use of biomarkers and early CT
scans in pre-emptive groups may favour the identiﬁcation of
IFD, especially of probable IFD, because the second version
of the European Organization for Research and Treatment
of Cancer-Mycoses Study Group (EORTC-MSG) deﬁnitions
[58] where one positive GM test and a lung lesion are
enough for a diagnosis of probable IA. As for antifungal use
and cost, there is no doubt that any pre-emptive approach
decreases antifungal use during neutropenia [31,33,41].
However, the administration of antifungals to treat IFD
after neutrophil recovery and the costs of diagnostic
procedures should also be considered.
 Whether prophylactic measures impact on the strategy
efﬁcacy is unclear. Marr et al. have suggested that mould-ac-
tive antifungals could decrease the sensitivity of GM [59]. In
our experience, laminar-air-ﬂow rooms were protective
against IA [39]. The choice of prophylactic measures should
logically impact on the choice of the strategy during
neutropenia, but few data are available. Similarly, the use
of scores to assess the fungal risk should help [60].
 In our experience [31], by combining GM and clinical
criteria, the pre-emptive administration of antifungals was
more often triggered by pulmonary symptoms than by
positive GM tests. On the other hand, 40% of our patients
with persistent or recurrent fever in the empirical group had
some concomitant clinical symptom, in addition to fever,
when antifungals were started. So, daily clinical assessment
remains essential, even when using the most sophisticated
diagnostic procedures.
What Next?
Using the experience of the French trial and its pitfalls [31], a
large EORTC prospective trial comparing a purely empirical
approach to a GM and CT scan based pre-emptive approach
has been designed (NCT01288378) with some differences to
improve the power of the study:
 All the patients receive ﬂuconazole prophylaxis.
 Only high-risk patients, namely patients with AML at
induction and allogeneic myeloablative transplant recipients
at the neutropenic phase, are included.
 Caspofungin is used in both arms instead of amphotericin-B.
However, caspofungin and liposomal amphotericin-B are
both licensed for the empirical indication.
We hope that this study will clarify the conﬂicting results of
the previous studies and provide the clinician with a useful
message for daily practice.
Conclusion
Many studies assessing pre-emptive antifungal strategies have
been published or are running. This occurs in parallel with
considerable progress in antifungal prophylaxis of neutropenic
patients. Two large studies showed a signiﬁcantly higher
incidence of IFD with a pre-emptive strategy when compared
with an empirical strategy [31,43] and no large study has so far
shown that the overall survival is not impaired by a pre-emp-
tive approach in the more at-risk patients. Pending the results
of additional trials, the empirical approach remains easy,
reproducible and safe when neutropenia lasts more than 10–
15 days. It is a costly strategy in terms of antifungals, but cheap
in terms of diagnostic procedures. For neutropenia of shorter
duration (<10 days), the beneﬁt of both strategies is similar,
and both are even debatable considering the low risk of IFD in
that setting [31]. In the case of efﬁcient anti-mould prophylaxis
by drugs or environmental procedures, the low risk of IFD
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should favour a pre-emptive strategy but a low performance of
the biomarkers should be expected. Pre-emptive strategies in
other settings should be explored prospectively and com-
pared, and eventually combined, with the more efﬁcient
prophylaxis.
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